1. Scrip
  2. >>Business
  3. >>Strategy

Bioqube Takes The Reins At J&J Innovation's JLINX

 
• By Nancy Dvorin

The recently launched venture capital firm has partnered with J&J Innovation to manage its new European life sciences incubator. START-UP speaks with bioqube's managing partner Nico Vandervelpen.

Johnson & Johnson Innovation has added to its network with the launch of a new initiative in Europe that combines venture investment and company incubation. Called JLINX, it is intended to catalyze scientific innovation and successful company formation by offering start-ups flexible ways to grow and collaborate across the European life sciences ecosystem.

Located in a fully dedicated facility on the Johnson & Johnson/Janssen Pharmaceutica NV campus in Beerse, Belgium, JLINX...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.